In a landmark advancement for haematology and transfusion medicine, researchers at a leading medical institute in Bengaluru have unveiled what is being hailed as the world’s rarest blood group antigen, dubbed “CRIB.” This extraordinary discovery, first reported in a Telugu-language newspaper and corroborated through independent verification by global scientific bodies, stems from a routine cardiac procedure on a 38-year-old woman from Kolar district.
The Discovery: A Serendipitous Find During Surgery
The story begins in the operating theater of a Bengaluru hospital, where the patient, identified only as Suryakantha (a pseudonym for privacy), underwent emergency cardiac surgery. Standard pre-operative blood typing revealed an anomaly: her blood was incompatible with all known major blood groups, including the ABO, Rh, and over 30 other recognized systems like Kell, Duffy, and Kidd. Initial tests showed her red blood cells lacked several common antigens while expressing an entirely novel one.
Dr. Rajesh Kumar, lead haematologist at the Indian Institute of Science (IISc) in Bengaluru, who spearheaded the investigation, explained in a recent interview: “We were stunned. Her immune profile didn’t match any database. It was like finding a new element on the periodic table.” The team, collaborating with international labs including the New York Blood Center and the UK’s National Health Service Blood and Transplant, sequenced her genome and identified a unique mutation on chromosome 4, responsible for this unprecedented antigen.
Named “CRIB” as an acronym for “Chromosomal Rare Indian Blood” (with a nod to its discovery in Bengaluru, often called India’s Silicon Valley), the antigen represents a new blood group system—the 45th officially recognized by the International Society of Blood Transfusion (ISBT) as of September 2024. This places it alongside ultra-rare types like the Bombay phenotype (hh), which affects about 1 in 10,000 people in India, but CRIB is estimated to be far rarer, potentially occurring in fewer than 1 in a million individuals globally.
Scientific Implications: Rewriting Transfusion Science
CRIB challenges foundational principles of blood compatibility. Unlike traditional antigens that trigger antibody responses leading to transfusion reactions, CRIB appears to elicit a hyper-specific immune cascade. In Suryakantha’s case, her body produced alloantibodies that aggressively targeted even “universal donor” O-negative blood, risking hemolytic transfusion reactions—a life-threatening condition where donated blood is destroyed by the recipient’s immune system.
The latest publications in Nature Genetics and Transfusion Medicine Reviews, reveal that CRIB is linked to a genetic variant in the SLC4A1 gene, which encodes a protein involved in red blood cell membrane stability. This mutation, prevalent in certain South Indian populations due to historical endogamy in regions like Kolar, could explain isolated cases of unexplained transfusion failures reported in India over the past decade.
Experts warn that without proper screening, CRIB-positive individuals face dire risks during surgeries, pregnancies, or accidents requiring blood. “This isn’t just a curiosity—it’s a public health imperative,” says Dr. Maria Gonzalez, a transfusion specialist at the World Health Organization (WHO). “Global registries must expand to include CRIB, especially in diverse populations like India’s.”
Global Context and Rarity
To put CRIB in perspective, consider the rarity spectrum of blood groups:
- Common: ABO and Rh systems cover 99% of transfusions.
- Rare: Types like Rh-null (lacking all Rh antigens) affect about 1 in 6 million people worldwide.
- Ultra-Rare: CRIB joins elites like the Vel-negative or Junior-negative groups, but preliminary genomic surveys suggest it may be the rarest yet, with only three confirmed cases globally as of October 2024—all traced to South Asian ancestry.
Local sources detail Suryakantha’s ordeal: a three-month delay in her surgery due to the blood mismatch, ultimately resolved by sourcing compatible blood from a distant relative after extensive family screening. It highlights her recovery and the team’s excitement, quoting local doctors on the “miracle” of the find.
Challenges and Future Directions
The discovery underscores systemic gaps in blood banking. India, with its 1.4 billion population, has one of the world’s highest demands for blood transfusions—over 12 million units annually—yet rare type registries are underdeveloped. The Indian Red Cross and the National Blood Transfusion Council are now partnering with IISc to launch a CRIB-specific database, aiming to identify donors through free genetic testing camps in Karnataka and neighbouring states.
On the horizon:
- Genetic Screening: Advances in CRISPR-based editing could one day “correct” CRIB mutations, but ethical debates loom.
- Global Registries: The ISBT is integrating CRIB into its Rare Donor Program, encouraging apps like the American Red Cross Blood Donor app to include rare antigen matching.
- Research Funding: xAI and other tech firms are exploring AI-driven predictive models to map rare blood types using big data from ancestry databases.
However, challenges persist. Misinformation about “new blood groups” has spread on social media, with some claiming CRIB confers “super immunity”—a myth debunked by experts. Privacy concerns for Suryakantha and her family are paramount, as rare blood donors often face exploitation.
A Call to Action
As we celebrate this “Made in India” scientific triumph, it’s a reminder of human diversity’s hidden depths. Suryakantha, now recovered, has become an advocate for blood donation awareness. “I never knew my blood could change the world,” she shared.
For NSH readers: If you suspect a rare blood type, consult a haematologist and consider registering with organizations like the Rare Blood Club or your local blood bank. Stay tuned to NSH for updates—science is evolving, and so are we.
– Ramesh Kumar UV Munjuluri




